Zhao Yan, Shi Cynthia X, McGoogan Jennifer M, Rou Keming, Zhang Fujie, Wu Zunyou
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Addiction. 2015 Jan;110 Suppl 1(Suppl 1):40-50. doi: 10.1111/add.12782.
The objective of this study was to examine factors that predict antiretroviral therapy (ART) access among eligible, HIV-positive methadone maintenance treatment (MMT) clients. We also tested the hypothesis that sustained MMT participation increases the likelihood of accessing ART.
A nation-wide cohort study conducted from 1 March 2004 to 31 December 2011.
MMT clients were followed from the time of their enrolment in China's national MMT programme until their death or the study end date.
Our cohort comprised 7111 ART-eligible, HIV-positive MMT clients, 49.2% of whom remained ART-naive and 50.8% of whom received ART.
Demographic variables, drug use history, MMT programme participation and HIV-related clinical characteristics of study participants who remained naive to ART and those who accessed ART were compared by univariate and multivariable analysis.
Predictors of accessing ART among this cohort included being retained in MMT at the time of first meeting ART eligibility [adjusted odds ratio (AOR)=1.84, confidence interval (CI)=1.54-2.21, P<0.001] compared to meeting ART eligibility before entering MMT (AOR=0.98, CI=0.80-1.21, P=0.849) or previously entering MMT and dropping out before meeting ART eligibility. Additional predictors were CD4≤200 cells/μl when ART-eligibility requirement was first met (AOR=1.81, CI=1.61-2.05, P<0.001 compared to CD4=201-350 cells/μl), and being in a stable partner relationship (married/cohabitating: AOR=1.14, CI=1.01-1.28, P=0.030).
Retained participation in methadone maintenance treatment increases the likelihood that eligible clients will access antiretroviral therapy. These results highlight the potential benefit of colocalization of methadone maintenance treatment and antiretroviral therapy services in a 'one-stop-shop' model.
本研究旨在探讨预测符合条件的HIV阳性美沙酮维持治疗(MMT)患者获得抗逆转录病毒治疗(ART)的因素。我们还检验了持续接受MMT治疗会增加获得ART可能性的假设。
一项于2004年3月1日至2011年12月31日进行的全国性队列研究。
MMT患者从纳入中国国家MMT项目开始,直至死亡或研究结束日期,均接受随访。
我们的队列包括7111名符合ART治疗条件的HIV阳性MMT患者,其中49.2%从未接受过ART治疗,50.8%接受过ART治疗。
通过单因素和多因素分析,比较了从未接受过ART治疗的研究参与者和接受过ART治疗的研究参与者的人口统计学变量、药物使用史、MMT项目参与情况以及与HIV相关的临床特征。
在该队列中,获得ART治疗的预测因素包括在首次符合ART治疗条件时仍在接受MMT治疗(调整后的优势比[AOR]=1.84,置信区间[CI]=1.54-2.21,P<0.001),与在进入MMT之前符合ART治疗条件(AOR=0.98,CI=0.80-1.21,P=0.849)或之前进入MMT但在符合ART治疗条件之前退出相比。其他预测因素包括首次满足ART治疗条件时CD4≤200个细胞/μl(与CD4=201-350个细胞/μl相比,AOR=1.81,CI=1.61-2.05,P<0.001),以及处于稳定的伴侣关系(已婚/同居:AOR=1.14,CI=1.01-1.28,P=0.030)。
持续参与美沙酮维持治疗可增加符合条件的患者获得抗逆转录病毒治疗的可能性。这些结果凸显了在“一站式”模式中将美沙酮维持治疗和抗逆转录病毒治疗服务并置的潜在益处。